SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 53 of 94
Word Count: 1451
Character Count: 9609

Document Content:

2020 with a business address at Muehlenhof 7-9, 40721 Hilden, registered with the commercial register of the local court (Amtsgericht) in Duesseldorf under HRB 90756. Our lead device program, the Revivent System, has a CE mark in Europe (where we have obtained approval but are currently not commercially operating in order to preserve capital) and is in its pivotal trial in the United States. We also have ownership rights to Alginate, a hydrogel-based device treatment for HFrEF patients without anterior scarring. This device was CE-marked in Europe and had received an IDE in the U.S. (though the CE-mark has lapsed and utilizing the IDE would require a meeting with the FDA regarding a proposed plan). MANAGEMENT Executive Officers and Directors The following table sets forth information regarding our executive officers and directors as of the date of this prospectus. Name Age Position David Richmond 54 Chairman and Co-Chief Executive Officer

Steven
Chartier 57 President,
Co-Chief Executive Officer, and Director

Carl E. Byrnes, Jr. 62 Chief Financial Officer

Ori Ben-Yehuda 66 Chief
Medical Officer

Mark
Ravich 73 Independent
Director

Rishi Puri 48 Independent
Director

William Abraham 66 Independent
Director

Executive
Officers

David
Richmond has been our Chairman, President and Co-Chief Executive Officer since January 2024. Mr. Richmond also served
as our chief financial officer from January 2024 through April 2026. Prior to that, from July 2019, Mr. Richmond was a board observer
of our Board before being asked to become a full board member in August 2021. Since 1994, Mr. Richmond has also been the founding partner
and Chairman of Richmond Brothers, Inc. (“RBI”), an SEC registered investment advisor. Mr. Richmond has been responsible
for the strategic planning of RBI and its affiliates, led the creation of RBI private funds, and sits as committee chairman for overall
client asset allocation. RBI private funds specialize in (but are not limited to) biotech, pharma, specialty pharma, and medical device
companies. RBI private funds prefer to focus on disruptive companies developing their first drug or device changing the paradigm in the
area in which they operate.

Richmond earned his BA in Marketing from Michigan State University in 1994. He earned his Master of Science in Financial Services
(MSFS) as well as his CLU, ChFC, CAP designations from the American College. Mr. Richmond is a Certified Public Company Director through
the UCLA Anderson School of Management (2021).

Carl
E. Byrnes, Jr. has served as our chief financial officer since April 2026. Prior to joining the Company, Mr. Byrnes served
as Managing Director and Senior Research Analyst – Healthcare at Northland Capital Markets from 2017 to 2026, where he
covered biotechnology, pharmaceutical, and medical device companies and advised institutional investors and corporate management
teams on capital markets strategy, valuation, and financing.

Previously,
Mr. Byrnes served as Senior Equity Research Analyst – Healthcare at Lake Street Capital Markets from 2015 to 2016. From 2016
to 2017, he operated Carl E. Byrnes Advisory Services LLC, an independent strategic advisory practice focused on strategic
transactions, including advising companies on sale processes, buyer engagement, and transaction execution. Mr. Byrnes previously
served as Chief Executive Officer of SCS Refrigerated Services from 2009 to 2013 and as Chief Financial Officer from 2008 to 2009,
where he led the recapitalization and sale of the company. Earlier in his career, he held roles at Pfizer Inc. from 2001 to 2006 in
investor relations and business intelligence, including participation in strategic initiatives and merger integration activities. He
began his career in investment banking at Montgomery Securities and later served in equity research roles at RBC Capital Markets and
Lehman Brothers.

Byrnes has served as Finance Committee Chairman, Treasurer, and Trustee of the Pacific Northwest Research Institute. He received a Bachelor
of Arts degree from Washington University in St. Louis in 1986 and an M.B.A. from Cornell University in 1990. Mr. Byrnes holds FINRA
registrations, including the Securities Industry Essentials (SIE), Series 7, Series 63, and Series 86/87 licenses, and has been registered
as a research analyst and general securities representative.

Steven
Chartier has been our President, Co-Chief Executive Officer, and Director since Jan 15, 2025. With over 30 years of experience
in the medical device and biotechnology industries, Mr. Chartier has demonstrated leadership in both large organizations and startup
environments. Prior to his current role, from January 2024 to January 2025, he served as Vice President of Regulatory and Quality at
Conformal Medical, Inc., a company specializing in cardiovascular left atrial appendage devices. His previous tenure at BioVentrix, spanning
from December 2021 to December 2023, included serving as Chief Operating Officer. Mr. Chartier was Vice President of Clinical Operations
at Sirtex Medical from September 2020 to December 2021. Mr. Chartier has also held key positions at Cardiovascular Clinical Sciences
(2019-2020), Anika Therapeutics (2017-2019), and InfraReDx (2007-2015), where he developed expertise in clinical operations, regulatory
affairs, quality assurance, and manufacturing. Notably, at Anika Therapeutics, he was Vice President of Regulatory and Clinical Affairs,
overseeing global regulatory strategies and clinical development for the company’s orthobiologics and regenerative medicine pipeline.
Mr. Chartier began his career in clinical research and trial coordination at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical
Center. Mr. Chartier earned a Bachelor of Arts in Psychology from Saint Anselm College in 1990 and obtained Regulatory Affairs Certification
from the Regulatory Affairs Professional Society in 2003.

Ori Ben-Yehuda has been our Chief Medical Officer since January 2024 and is a distinguished clinical cardiologist and
clinical trialist with over 25 years of experience in treating patients with coronary disease, myocardial infarction, and heart failure.
In addition to his role at BioVentrix, Dr. Ben-Yehuda is a Professor of Medicine at the University of California, San Diego (UCSD), where
he leads the Cardiovascular Outcomes Group at the Sulpizio Cardiovascular Institute. Dr. Ben-Yehuda also holds editorial positions as
Editor-in-Chief of Coronary Artery Disease and Deputy Editor of Structural Heart: The Journal of the Heart Team. Dr. Ben-Yehuda’s
previous roles include Executive Director of the Clinical Trials Center at the Cardiovascular Research Foundation and Vice President
of Cardiovascular Clinical Trials at Gilead Sciences. Dr. Ben-Yehuda has authored and co-authored over 200 peer-reviewed publications
and has been recognized with multiple awards, including Top Abstract at the TCT Conference in 2017 and the Sackler Faculty Prize for
Excellence for his MD thesis. Dr. Ben-Yehuda earned his medical degree from the Sackler School of Medicine at Tel Aviv University in
Israel and completed a cardiovascular medicine fellowship at UCSD.

Independent Directors

Mark
H. Ravich has served as a director since July 2025. Since June 2017, Mr. Ravich has been a director of Rockwell
Medical (Nasdaq: RMTI), a pharmaceutical company, and is currently a member of its audit committee. Mr. Ravich also currently serves
as president of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998. From
October 2010 through December 2022, Mr. Ravich served as a director of Dilon Technologies, Inc., a designer and manufacturer of medical
imaging solutions. In addition, from February 2019 to March 2023, Mr. Ravich previously served as a director of BioVentrix. Previously,
from February 2013 to 2018, Mr. Ravich served as a director of Orchids Paper Products Company, a national supplier of high-quality consumer
tissue products, as well as chairman of its governance committee and as a member of its audit committee. Orchids Paper Products Company
filed for Chapter 11 bankruptcy on April 1, 2019, in the U.S. Bankruptcy Court for the District of Delaware. From June 2004 to 2018,
Mr. Ravich served as a director of MR Instruments, Inc., an independent designer and manufacturer of advanced MRI Radiofrequency coils.
From 1990 until its sale in 1998, Mr. Ravich served as the chief executive officer and a director of Universal International, Inc., a
wholesale retail company, where he also led its initial public offering. From 1978 to 1990, Mr. Ravich was a developer of commercial
real estate where he was involved with all aspects of development, finance, construction, marketing, leasing and management of various
commercial, industrial, office and multi-family real estate projects. Mr. Ravich began his career in 1975 as an account officer at Citibank
N.A., where he made real estate construction loans to national real estate developers. Mr. Ravich also is the chief manager of various
real estate entities. Mr. Ravich graduated Magna Cum Laude from the Wharton School of the University of Pennsylvania with a B.S. and
an M.B.A. degree with a major in finance. We believe that Mr. Ravich’s extensive board experience across the pharmaceutical, medical
device, and real estate sectors, combined with his financial expertise and leadership in both public and private companies qualifies
him to be a member of our board of directors.

Rishi
Puri, M.D., Ph.D., FRACP, FACC has served as a director since July 2025.